Government
City of San Diego
City of San Diego $40M Water Rate Settlement
Gritstone bio
Gritstone bio investors who bought common stock between March 2023 and April 2024 can claim a pro rata share of a $6M settlement before Nov. 13, 2026.
openclaimslist.com Editorial Team ·

Check your eligibility before accessing the claim form.
View the placeholder advertisement, then continue to reveal the claim link.
The claim deadline has passed.
Investors who purchased Gritstone bio, Inc. common stock (Nasdaq: GRTS) between March 9, 2023, and April 2, 2024, may qualify to claim a pro rata cash payout from a $6 million securities class action settlement. The lawsuit alleges that the biotechnology company and former executives misled investors regarding its vaccine clinical trial results and overall financial outlook. With the claim deadline rapidly approaching on November 13, 2026, eligible shareholders should review their transaction records to ensure they do not miss out on potential financial compensation.
Deadline: November 13, 2026 — Claims must be submitted online or postmarked by 11:59 p.m. Eastern Time to qualify for a pro rata payout from the $6 million fund.
The class action lawsuit, titled In re Gritstone bio, Inc. Securities Litigation (Case No. 3:24-cv-03640-CRB), is pending in the U.S. District Court for the Northern District of California before Judge Charles R. Breyer. The litigation claims that Gritstone made materially false and misleading statements to the public regarding the clinical progress and commercial viability of its leading vaccine candidates. According to the complaint, when the true facts concerning clinical setbacks and capital constraints were disclosed, the value of Gritstone common stock dropped significantly, harming retail and institutional shareholders alike.
While Gritstone bio subsequently filed for Chapter 11 bankruptcy protection in Delaware in October 2024, this $6 million settlement is funded by insurers covering former CEO Andrew R. Allen. Strategic Claims Services is administering the distribution of the settlement funds. Because Gritstone itself is in bankruptcy, this insurance-backed fund represents the primary recovery avenue for shareholders who suffered losses during the designated class period.
You are part of the settlement class if you purchased or otherwise acquired Gritstone bio common stock between March 9, 2023, and April 2, 2024, inclusive.
You likely qualify if:
Shares purchased on or after April 2, 2024, including those issued in the April 2024 public offering, are excluded from recovery under the court-approved plan of allocation. Furthermore, publicly traded options and warrants are not directly eligible, though common stock acquired through the exercise of an option or warrant during the class period is treated as a purchase on the execution date.
Payouts from the Gritstone bio settlement are distributed on a pro rata basis, meaning your individual recovery depends on the total volume of valid claims submitted and your net recognized losses. Early estimates suggest an average payout of approximately $0.11 per damaged share before administrative costs and attorney fees are deducted. If you held shares when trading was suspended in October 2024, your loss calculations will factor in the plan’s 90-day look-back period, which applies an average closing price of $0.82 per share.
| Claim Type | Maximum Amount | Documentation Needed | |---|---|---|> | Recognized Stock Loss | Pro Rata (Est. $0.11/share) | Brokerage statements or confirmations | | Alternative Claim | Varies by calculation | Transaction history and proof of ownership |
Because the settlement fund is fixed at $6 million, actual per-share distributions will decrease if total verified claims exceed available funds, or increase proportionately if fewer claims are filed.
| Event | Date |
|---|---|
| Claim Deadline | November 13, 2026 |
| Opt-Out Deadline | October 14, 2026 |
| Objection Deadline | October 14, 2026 |
| Final Approval Hearing | December 4, 2026 |
| Estimated Payment Date | TBD after final approval |
Filing a claim requires gathering your financial documentation and submitting a completed Proof of Claim and Release form to the settlement administrator.
Eligible investors who take no action and fail to submit a timely claim form will receive zero compensation from the $6 million settlement fund. At the same time, inactive class members remain legally bound by the settlement terms and lose all rights to sue Gritstone bio, its former executives, or its insurers independently regarding these securities claims.
This securities class action settlement resolves investor allegations that Gritstone bio and former leadership misled shareholders about clinical trial results, resulting in stock devaluation. A $6 million insurance-backed fund has been established to compensate investors who purchased common stock during the specified class period in 2023 and 2024.
You are included if you purchased Nasdaq-traded Gritstone common stock between March 9, 2023, and April 2, 2024. Shares acquired outside this timeframe or through specific exempted offerings do not qualify for recovery under the court-approved allocation plan.
Individual payouts depend on your net recognized losses and the total volume of approved claims filed by other investors. Current estimates project an average recovery of roughly $0.11 per damaged share, subject to pro rata adjustment.
No, you do not need to hire an attorney to participate in this settlement. Investors can file claims independently online or by mail using the official forms provided by the court-appointed claims administrator.
Payments will be distributed only after the court holds the final approval hearing on December 4, 2026, and enters a formal judgment approving the settlement and plan of allocation. This process typically takes several months following final approval.
Gritstone bio filed for Chapter 11 bankruptcy protection in October 2024, meaning the company cannot directly fund cash recoveries. Instead, the $6 million settlement is provided entirely by insurance policies covering former CEO Andrew R. Allen.
Publicly traded options and warrants are not eligible securities for direct claims. However, common stock acquired by exercising an option or warrant during the class period is treated as a purchase on the execution date using the exercise price.
Time is running out for eligible investors to secure their share of the $6 million recovery fund. With payouts estimated on a pro rata basis and a strict submission cutoff, failing to act means forfeiting your rightful compensation. If you purchased Gritstone bio common stock between March 2023 and April 2024, check your brokerage records and submit your claim before the November 13, 2026 deadline.
This article is for informational purposes only and does not constitute legal advice.
Government
City of San Diego $40M Water Rate Settlement
Data Breach
California Casualty $4K Data Breach Settlement
Data Breach
International Shoppes $500K Data Breach Settlement